Aliases:This biomarker is also known as:
AFP is a major plasma protein produced by the yolk sac and the liver during fetal life. Alpha-fetoprotein expression in adults is often associated with hepatoma or teratoma. However, hereditary persistance of alpha-fetoprotein may also be found in individuals with no obvious pathology. The protein is thought to be the fetal counterpart of serum albumin, and the alpha-fetoprotein and albumin genes are present in tandem in the same transcriptional orientation on chromosome 4. Alpha-fetoprotein is found in monomeric as well as dimeric and trimeric forms, and binds copper, nickel, fatty acids and bilirubin.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
No additional data available.
Ninety biomarkers were measured using a series of multiplexed immunoassays and results analyzed by the EDRN data management center splitting the cases and controls into training and validation sets, excluding subjects with DCIS or atypical hyperplasia from the training phase. We found little evidence that any of these markers can discriminate women with invasive cancer from those with benign breast conditions.
|QA State:||Under Review|
Since 90% of patients with hepatocellular carcinoma (HCC) have underlying cirrhosis, patients with cirrhosis are candidates for HCC surveillance. Despite advances in medical technology, the 5-year survival of patients with HCC has improved minimally from 2% to 5% from 1981 to 1998. This may be largely due to diagnosis at late stage disease. These studies aim to compare the performance characteristics of the biomarkers AFP, DCP (des-gamma carboxyprothrombin) and AFP-L3 (lectin-bound AFP) in the early diagnosis of HCC.
AFP has been approved by the FDA as a component of lab test to diagnose the risk of developing liver cancer in patients with chronic liver disease (CLD). The test measures levels of both AFP-L3 and AFP in the blood, and calculates AFP-L3 levels as a percentage of total AFP. Higher levels of AFP-L3 are associated with higher risk of developing liver cancer. According to the FDA, if the percentage of AFP-L3 is greater or equal to 10%, the risk is seven-fold that the patient will develop liver cancer in the next 21 months.
|QA State:||Under Review|
- HGNC entry for AFP from Genenames
- KEGG entry for AFP from Genome.jp
- Entrez entry for AFP all NCBI Databasese
- Human GEO Profiles for AFP from NCBI GEO Profiles
- Human Geo Datasets containing term AFP from NCBI GEO Datasets
- GWAS Study Datasets containing gene AFP from GWAS
- Human Single Nucleotide Polymorphisms info for AFP
- Human Gene(s) with 'AFP' as Gene Name/Alias
- Human Gene RefSeq for AFP from NCBI
- GeneCards entry for human AFP
- UniProtKB/Swiss-Prot entry for AFP from Uniprot
- Human Protein RefSeq for AFP from NCBI
- FDA web page describing approval of AFP
No other associated resources found.
|UniProt Accession #:||P02771|
|Mutated Sites Count:||100|
|Associated Pubmed ID Count||13|
|Affected Protein Function Sites Count:||4|